<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03264937</url>
  </required_header>
  <id_info>
    <org_study_id>2017-P-033</org_study_id>
    <nct_id>NCT03264937</nct_id>
  </id_info>
  <brief_title>Social Software to iMprove mAnagement of oRal Anticoagulation Therapy</brief_title>
  <acronym>SMART</acronym>
  <official_title>A Social Software-based Management Strategy to Improve Quality of Oral Anticoagulation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Asia Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan Asia Heart Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, observational, randomized controlled trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Social softwares is becoming necessaries of life. Wechat, powered by Tencent company, is the
      most popular social software in China. People can chat with others no matter how far away
      from each other.

      Quality of anticoagulation therapy is very important for patients receiving warfarin
      ancoagualtion therapy, which is evaluated by employing Time in therapeutic range (TTR). It is
      reported that TTR is very low in China patients. SO we are planing to introduce the social
      software to set up a bridge for clinicians and their patients, to improve patients
      educations, anticoagulation managements, anticoagulation knowledge publicity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombotic events</measure>
    <time_frame>24 months</time_frame>
    <description>Stroke,TIA,Peripheral vascular embolization，Transient ischemic attack etc.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major bleeding events</measure>
    <time_frame>24 months</time_frame>
    <description>cerebral hemorrhage，gastrointestinal bleeding etc.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Deaths</measure>
    <time_frame>24 months</time_frame>
    <description>All-cause deaths</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time in therapeutic range</measure>
    <time_frame>24 months</time_frame>
    <description>Time in therapeutic range of international normalized ratio</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Anticoagulants Causing Adverse Effects in Therapeutic Use</condition>
  <condition>Patient Compliance</condition>
  <arm_group>
    <arm_group_label>Wechat-based group</arm_group_label>
    <description>We set up a chat-group in wechat application, and pulled participatients' ID in this chat-group. We send anticoagulation knowledges, answer questions, remind them of monitoring INR et.al.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>We just observe without any additional contacts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Wechat-based management</intervention_name>
    <description>Using Wechat application, a social software, to educate and remind patients during oral warfarin anticoagulation therapy.</description>
    <arm_group_label>Wechat-based group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients are those who receiving oral warfarin anticoagulation therapy because of
        mechanical valve replacement, or atrial fibrillation .
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Receiving warfarin anticoagulation therapy

          -  Have smartphone

          -  Know how to use wechat applicaiton

        Exclusion Criteria:

          -  No compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Zhenlu Zhang, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Wuhan Asia Heart Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Litao ZHANG, MD</last_name>
    <phone>15623010240</phone>
    <email>zhangleetau@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>WAHH</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhang litao, MD</last_name>
      <phone>+86 15623010240</phone>
      <email>zhangleetau@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2017</study_first_submitted>
  <study_first_submitted_qc>August 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2017</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TTR</keyword>
  <keyword>INR</keyword>
  <keyword>Warfarin</keyword>
  <keyword>social software</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>We are going to make individual participant data (IPD) available to other researchers after our paper published</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

